SAN DIEGO, Feb. 11, 2019 (GLOBE NEWSWIRE) — Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need, today announced that Joseph Payne, President & CEO, will present at three investor conferences in February and March 2019: BIO CEO & Investor Conference, Leerink 8th Annual Global Healthcare Conference, and 31st Annual ROTH Conference.
| BIO CEO & Investor Conference | ||
| Presenter: | Joseph Payne | |
| Date: | Monday, February 11 | |
| Time: | 9:15am Eastern Time | |
| Location: | New York Marriott Marquis, New York City | |
| Leerink 8th Annual Global Healthcare Conference | ||
| Presenter: | Joseph Payne | |
| Date: | Wednesday, February 27 | |
| Time: | 11:30am Eastern Time | |
| Location: | Lotte New York Palace, New York City | |
| 31st Annual ROTH Conference | ||
| Presenter: | Joseph Payne | |
| Date: | Monday, March 18 | |
| Time: | 11:00am Pacific Time | |
| Location: | The Ritz Carlton, Laguna Niguel, Orange County, CA | |
About Arcturus Therapeutics Ltd.
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Ltd. (NASDAQ: ARCT) is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR® lipid-mediated delivery. Arcturus’ diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its extensive patent portfolio (150 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. Arcturus’ commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG and the Cystic Fibrosis Foundation. For more information, visit www.Arcturusrx.com, the content of which is not incorporated herein by reference.
Contact
Neda Safarzadeh
Arcturus Therapeutics
(858) 900-2682
[email protected]
Arcturus Investor Contact
Michael Wood
LifeSci Advisors LLC
(646) 597-6983
[email protected]
